Medpace (MEDP) Q1 2026 earnings review
Strong Revenue Growth Masks Book-to-Bill Collapse and Margin Compression
Medpace delivered robust 26.5% YoY revenue growth in Q1, but underlying fundamentals are flashing warning signs. The net book-to-bill ratio dropped to a troubling 0.88x, confirming that the rapid revenue burn (23.3% conversion rate) is vastly outstripping the intake of new business awards. Meanwhile, a massive 54% spike in zero-margin reimbursed out-of-pocket expenses crushed profitability, driving net income margin down 300 basis points to 17.5%. The sudden resignation of President Jesse Geiger adds an unexpected layer of leadership uncertainty to a quarter defined by a widening disconnect between top-line momentum and forward-looking booking health.
🐂 Bull Case
The company continues to efficiently execute its existing $2.93 billion backlog. The high conversion rate of 23.3% acts as a near-term revenue shield, driving 25.8% constant-currency revenue growth despite the soft booking environment.
Despite Q1's booking struggles and executive turnover, management reaffirmed the FY26 guidance targets established in Q4, signaling confidence in their full-year revenue and EBITDA trajectories.
🐻 Bear Case
A 0.88x book-to-bill ratio is a significant red flag. Backlog only grew 2.9% YoY, meaning the company is eating into its future pipeline to sustain current growth rates. This dynamic is unsustainable over the long term.
Net income growth (+8.1%) lagged significantly behind revenue growth (+26.5%) as zero-margin reimbursable out-of-pocket expenses surged. This structural shift in study mix continues to compress bottom-line profitability.
⚖️ Verdict: 🔴
Bearish. The impressive YoY top-line growth is a rearview mirror metric driven by an elevated burn rate. The forward-looking indicators—a 0.88x book-to-bill, compressing margins, and a sudden C-suite departure—paint a deteriorating operational picture.
Key Themes
Book-to-Bill Ratio Decelerating Alarmingly
The net book-to-bill ratio fell to 0.88x, reversing from 1.04x in 25Q4 and 1.20x in 25Q3. Net new business awards were $618.4 million—while an improvement over the disastrous 25Q1 ($500M), they fell sharply short of the $706.6 million in quarterly revenue. Backlog essentially flatlined sequentially and grew a meager 2.9% YoY. If Medpace cannot replenish its backlog faster than its 23.3% conversion rate, future revenue growth will face a severe cliff.
Surging Pass-Through Costs Driving Margin Compression
The margin profile is decelerating. GAAP Net Income margin dropped to 17.5% from 20.5% a year ago. The culprit is a massive mix shift: Reimbursed out-of-pocket expenses skyrocketed 54.1% YoY to $312.0 million, representing 44.1% of total revenue. By contrast, direct service costs (the core value-add business) grew only 11.5% YoY. This confirms management's prior warnings about the dilutive nature of their high-metabolic study mix.
Sudden Executive Departure
President Jesse Geiger announced his resignation, effective May 31, 2026. While the company stated this was not due to operational disagreements, a high-level executive departure during a period of weak bookings and margin compression creates additional execution risk. CEO August Troendle will temporarily absorb the President role.
Operating Cash Flow Remains Resilient
Despite margin pressures, operating cash flow demonstrated stable strength, generating $151.8 million in the quarter (up from $125.8 million in 25Q1). This underpins the company's strong balance sheet, which boasts $652.7 million in cash and cash equivalents, preserving flexibility for continued capital returns or strategic investments.
Other KPIs
Accelerating dramatically. These zero-to-low margin pass-through costs surged 54% YoY, heavily outpacing direct service cost growth. They now constitute 44.1% of total revenue, diluting the overall margin profile and making the top-line growth figure look artificially inflated relative to true operational value creation.
Reversing. SG&A actually declined YoY from $57.9 million in 25Q1. This cost control was critical in defending the EBITDA margin (21.1%), preventing the pass-through cost surge from doing even more damage to operating profits.
Guidance
Decelerating. Maintained from prior quarter. The midpoint implies a full-year YoY growth rate of roughly 10.8% over FY25's $2.53 billion. Given Q1's 26.5% YoY growth, this guidance requires a steep deceleration in the remaining three quarters of 2026, aligning with the weak leading indicators seen in the 0.88x book-to-bill ratio.
Decelerating. Maintained from prior quarter. The midpoint implies roughly 11% growth over FY25, tracking almost exactly with projected revenue growth. This signals that management does not expect meaningful margin expansion over the remainder of the year.
Stable. The implied diluted EPS guidance of $16.68 to $17.50 assumes a 19.0% to 20.0% full-year tax rate and does not account for the potential accretive impact of any unannounced share repurchases made after March 31, 2026.
Key Questions
President Resignation Timing
Jesse Geiger’s resignation comes amid a weak bookings quarter and margin compression. Can you elaborate on the transition plan and whether any strategic shifts in operational oversight will accompany his departure?
Path to Book-to-Bill Recovery
With the net book-to-bill ratio falling to 0.88x, what is the anticipated timeline for normalization? Are the current weakness patterns driven by elevated cancellations, delayed client funding, or outright market share losses to larger CROs?
Pass-Through Cost Ceiling
Reimbursable expenses reached 44.1% of revenue in Q1, exceeding the 41-42% normalized range guided in previous quarters. Is this the peak for the metabolic study mix, or should we expect pass-throughs to continue diluting margins throughout the balance of FY26?